News

Enzyme PRMT5 found to drive chemotherapy resistance in ovarian cancer
Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...
The Munich Eye2d
Research Identifies PRMT5 Enzyme as Key Factor in Ovarian Cancer Chemotherapy Resistance
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Hosted on MSN1mon
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company. Suzhou Puhe BioPharma is focused on the research and development of innovative ...
Nasdaq1mon
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine ...